Comparative efficacy and safety of biologic therapies in pediatric asthma: a comprehensive systematic review.

Front Med (Lausanne) · 2026 · PMC13038997 · PMID 41930104

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Omalizumab showed a trend toward fewer virus-related exacerbations (OR 0.52).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

While during stable steroid phase, omalizumab showed fewer asthma exacerbations compared to placebo but it did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.